vs
Side-by-side financial comparison of Home Federal Bancorp, Inc. of Louisiana (HFBL) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Home Federal Bancorp, Inc. of Louisiana is the larger business by last-quarter revenue ($6.0M vs $5.5M, roughly 1.1× Taysha Gene Therapies, Inc.). Home Federal Bancorp, Inc. of Louisiana runs the higher net margin — 27.8% vs -507.8%, a 535.6% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs 18.2%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs 10.7%).
Home Federal Bancorp, Inc. of Louisiana is a U.S. bank holding company based in Louisiana. It operates community banking services via its subsidiary, offering retail customers and local small businesses a full suite of financial products including deposit accounts, consumer loans, mortgage loans, and commercial financing, primarily serving local markets across Louisiana.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
HFBL vs TSHA — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.0M | $5.5M |
| Net Profit | $1.7M | $-27.9M |
| Gross Margin | — | — |
| Operating Margin | 35.1% | -516.0% |
| Net Margin | 27.8% | -507.8% |
| Revenue YoY | 18.2% | 171.3% |
| Net Profit YoY | 64.2% | -48.3% |
| EPS (diluted) | $0.54 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $6.0M | $5.5M | ||
| Q3 25 | $5.9M | $0 | ||
| Q2 25 | $5.6M | $2.0M | ||
| Q1 25 | $5.2M | $2.3M | ||
| Q4 24 | $5.1M | $2.0M | ||
| Q3 24 | $4.7M | $1.8M | ||
| Q2 24 | $4.9M | $1.1M | ||
| Q1 24 | $4.9M | $3.4M |
| Q4 25 | $1.7M | $-27.9M | ||
| Q3 25 | $1.6M | $-32.7M | ||
| Q2 25 | $1.2M | $-26.9M | ||
| Q1 25 | $748.0K | $-21.5M | ||
| Q4 24 | $1.0M | $-18.8M | ||
| Q3 24 | $941.0K | $-25.5M | ||
| Q2 24 | $638.0K | $-20.9M | ||
| Q1 24 | $732.0K | $-24.1M |
| Q4 25 | 35.1% | -516.0% | ||
| Q3 25 | 34.1% | — | ||
| Q2 25 | 27.5% | -1347.1% | ||
| Q1 25 | 18.3% | -930.5% | ||
| Q4 24 | 23.7% | -985.8% | ||
| Q3 24 | 19.9% | -1448.4% | ||
| Q2 24 | 16.9% | -1915.4% | ||
| Q1 24 | 18.5% | -713.3% |
| Q4 25 | 27.8% | -507.8% | ||
| Q3 25 | 27.1% | — | ||
| Q2 25 | 20.9% | -1353.6% | ||
| Q1 25 | 14.4% | -935.2% | ||
| Q4 24 | 20.0% | -929.0% | ||
| Q3 24 | 19.9% | -1427.5% | ||
| Q2 24 | 13.1% | -1882.0% | ||
| Q1 24 | 14.9% | -705.4% |
| Q4 25 | $0.54 | $-0.08 | ||
| Q3 25 | $0.52 | $-0.09 | ||
| Q2 25 | $0.38 | $-0.09 | ||
| Q1 25 | $0.24 | $-0.08 | ||
| Q4 24 | $0.33 | $-0.07 | ||
| Q3 24 | $0.31 | $-0.10 | ||
| Q2 24 | $0.21 | $-0.09 | ||
| Q1 24 | $0.24 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $57.7M | $246.9M |
| Total Assets | $621.4M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $319.8M | ||
| Q3 25 | — | $297.3M | ||
| Q2 25 | — | $312.8M | ||
| Q1 25 | — | $116.6M | ||
| Q4 24 | — | $139.0M | ||
| Q3 24 | — | $157.7M | ||
| Q2 24 | — | $172.7M | ||
| Q1 24 | — | $124.0M |
| Q4 25 | $57.7M | $246.9M | ||
| Q3 25 | $56.6M | $219.0M | ||
| Q2 25 | $55.2M | $248.7M | ||
| Q1 25 | $54.7M | $55.1M | ||
| Q4 24 | $53.9M | $71.5M | ||
| Q3 24 | $54.3M | $88.8M | ||
| Q2 24 | $52.8M | $108.9M | ||
| Q1 24 | $52.5M | $53.8M |
| Q4 25 | $621.4M | $343.3M | ||
| Q3 25 | $622.6M | $316.6M | ||
| Q2 25 | $609.5M | $333.3M | ||
| Q1 25 | $619.6M | $138.4M | ||
| Q4 24 | $607.8M | $160.4M | ||
| Q3 24 | $628.4M | $180.2M | ||
| Q2 24 | $637.5M | $200.4M | ||
| Q1 24 | $643.0M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.9M | $-26.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.70× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.9M | $-26.7M | ||
| Q3 25 | $2.8M | $-24.2M | ||
| Q2 25 | $5.5M | $-20.2M | ||
| Q1 25 | $991.0K | $-22.0M | ||
| Q4 24 | $2.6M | $-18.3M | ||
| Q3 24 | $871.0K | $-21.6M | ||
| Q2 24 | $2.3M | $-21.5M | ||
| Q1 24 | $650.0K | $-19.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-24.3M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-18.3M | ||
| Q3 24 | $843.0K | $-21.6M | ||
| Q2 24 | $2.3M | $-21.7M | ||
| Q1 24 | — | $-19.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -905.5% | ||
| Q3 24 | 17.8% | -1210.9% | ||
| Q2 24 | 46.8% | -1951.9% | ||
| Q1 24 | — | -584.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | 0.6% | 2.0% | ||
| Q2 24 | 0.8% | 18.1% | ||
| Q1 24 | — | 4.1% |
| Q4 25 | 1.70× | — | ||
| Q3 25 | 1.74× | — | ||
| Q2 25 | 4.64× | — | ||
| Q1 25 | 1.32× | — | ||
| Q4 24 | 2.54× | — | ||
| Q3 24 | 0.93× | — | ||
| Q2 24 | 3.63× | — | ||
| Q1 24 | 0.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
